University of Virginia Patent Foundation

Other

University System of Maryland

The Penn State Research Foundation

Emory University

Adenosine Therapeutics, LLC

Joel M Linden

Gail W Sullivan

Timothy L MacDonald

Jayson Michael Rieger

Robert Alan Figler

Lauren J Murphree

Robert Douglas Thompson

Mark D Okusa

Ian J Sarembock

W Michael Scheld

Peter J Scammells

Irving L Kron

Ray A Ollson

Kenneth Alan Jacobson

Thomas Piccariello

Richard Louis Price

Guoquan Wang

Victor H Engelhard

Barbara J Mann

Mahendra Devichand Chordia

Gary L Brooker

Wesley L Terasaki

Kenneth Brayman

Kathryn F LaNoue

George A Beller

David K Glover

Preeti Chhabra

Yong-Chul Kim

Courtney M Lappas

George H Crist

Amy L Tucker

George Vandenhoff

Heidi Taylor

Rebecca Youkey

Robin Woodard

Anna Robeva

Alaa S Awad

Xiaowei Jin

Donald L Kimpel

Shanthi V Sitaraman

Kenneth Lewis Brayman

Sanford Feldman

Yunge Zhao

Yuesheng Jason Li

Christine Lau

Kori Wallace

W Michael Sheld

Lauren Murphree Mihalcik

The present invention relates methods of treating cytokine storm syndrome comprising administering to a patient in need thereof a therapeutically effective amount of an adenosine Areceptor agonist.

Adenosine A2A agonists for the treatment of cytokine storm syndrome

The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of Aadenosine receptors (ARs).

Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease

The present invention is a method for treatment or prevention of injury to nerve cells. The method can use at least one Areceptor modulator to prevent injury to or enhance the healing of the injured cells.

[object Object]

The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount of an Aadenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).

Method to treat sickle cell disease

The invention provides compounds having the following general formula (I): 

2-propynyl adenosine analogs having A2A agonist activity and compositions thereof

The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of Aadenosine receptors (ARs).

Method of treating ischemia reperfusion injury by inhibiting NKT cell activity

2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity

2-polycyclic propynyl adenosine analogs having A2A agonist activity

Disclosed is the use of selective adenosine Aallosteric enhancers to induce angiogenesis at a desired location for treating conditions in which increased angiogenesis is desired, such as stroke, heart disease and peripheral vascular disease.

The invention provides compounds having the following general formula (I): wherein X, R, R, Rand Z are as described herein.

The present invention relates generally to a class of 2-aminothiazole derivatives which have recently been identified as allosteric enhancers of the A1? adenosine receptor. These compounds, and therapeutic compositions containing them, are useful for treating conditions in which activation of the A1? adenosine receptor would be beneficial, for example, those conditions in which stimulation of angiogenesis would improve blood flow to ischemic tissues.

The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an Aadenosine receptor agonist. If no anti-pathogenic agent is known the Aagonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.

Method to reduce inflammatory response in transplanted tissue

Growing community of inventors

Charlottesville, VA, United States of America

Joel M Linden